Updates are available Correction dated 2018-06-13
Click to view Correction: https://doi.org/10.1186/s10020-018-0030-9
-
Authors
He, Mingzhu http://orcid.org/0000-0001-7779-2411
Bianchi, Marco E.
Coleman, Tom R.
Tracey, Kevin J.
Al-Abed, Yousef
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (18623)
National Institutes of Health (S10 RR033072-01)
Feinstein Institute for Medical Research
- License Information
-
More Information
Article History
Received: 10 April 2018
Accepted: 1 May 2018
First Online: 10 May 2018
Change Date: 13 June 2018
Change Type: Correction
Change Details: After publication of this article (He et al., 2018), the corresponding authors recognised an error in Scheme 1, in particular to section “A. HMGB1/TLR4/MD-2 complex formation”. Above “Step 2: B box binding to MD-2”, the text incorrectly read: “Low affinity / extremely slow off”. In addition, some text was omitted below “TLR4/MD-2”. The correct version of Scheme 1 is included in this Correction article. The original article (He et al., 2018) has been corrected.
Ethics approval and consent to participate
: Not applicable.
: YAA is on patents related to HMGB1 antagonists, and MEB on patents related to the HMGB1 3S mutant.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
